Valuation: Beam Therapeutics Inc.

Market Cap 2.62B 2.3B 2.12B 1.95B 3.69B 253B 3.75B 25.35B 9.94B 124B 9.84B 9.63B 426B P/E 2026 *
-6.06x
P/E 2027 * -5.8x
Enterprise Value 1.77B 1.55B 1.43B 1.32B 2.49B 170B 2.53B 17.08B 6.7B 83.27B 6.63B 6.49B 287B EV / Sales 2026 *
22.4x
EV / Sales 2027 * 15.1x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
1 day+1.41%
1 week-19.43%
Current month-23.28%
1 month-22.88%
3 months-16.12%
6 months-15.66%
Current year-5.01%
1 week 26.19
Extreme 26.19
31.55
1 month 26.19
Extreme 26.19
38.26
Current year 21.63
Extreme 21.63
38.26
1 year 15.6
Extreme 15.6
38.26
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
116.91
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 31/12/2016
President 57 23/01/2020
Director of Finance/CFO 48 18/12/2024
Director TitleAgeSince
Director/Board Member 48 31/12/2016
Director/Board Member 75 30/04/2018
Director/Board Member 56 09/10/2019
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Sell

Chief Technology Officer

-373 0.0004%
30/06/26 Fiscal year

Chief Executive Officer

75,000 0.0729%
26/06/26
F-Prime Inc.
SellCompany -251,488 0.2444%
Change 5-day change 1-year change 3-year change Capi.($)
-4.36%-19.43%+26.89%-15.06% 2.74B
-0.49%-3.58%-0.84%+2.13% 49.18B
-3.10%-3.47%+370.99%+567.62% 39.58B
-0.46%+3.98%+5.44%+60.79% 34.69B
-1.14%-1.90%+26.94%-9.56% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-3.54%-6.91% - - 16.21B
-1.82%-1.91%+69.28%+112.51% 15.36B
+1.17%+3.10%+15.87%+16.79% 14.05B
-2.25%-0.92%+15.77%-32.78% 13.02B
Average -1.20%-1.73%+58.98%+81.61% 24.64B
Weighted average by Cap. -1.40%-0.55%+75.33%+116.07%

Financials

2026 *2027 *
Net sales 78.87M 69.11M 63.91M 58.75M 111M 7.61B 113M 763M 299M 3.72B 296M 290M 12.82B 96.07M 84.19M 77.85M 71.57M 135M 9.26B 137M 929M 364M 4.53B 361M 353M 15.61B
Net income -461M -404M -374M -344M -649M -44.47B -659M -4.46B -1.75B -21.74B -1.73B -1.69B -74.92B -521M -456M -422M -388M -733M -50.22B -745M -5.04B -1.97B -24.55B -1.96B -1.91B -84.62B
Net Debt -855M -749M -692M -637M -1.2B -82.41B -1.22B -8.27B -3.24B -40.29B -3.21B -3.14B -139B -1.17B -1.03B -950M -873M -1.65B -113B -1.68B -11.34B -4.44B -55.24B -4.4B -4.3B -190B
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
522
Date Price Change Volume
20/07/26 US$26.33 -4.36% 2,763,678
17/07/26 US$27.53 -3.03% 1,912,917
16/07/26 US$28.39 -7.94% 4,194,497
15/07/26 US$30.84 -0.16% 1,395,267
14/07/26 US$30.89 -0.35% 2,008,765
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
26.33USD
Average target price
52.31USD
Spread / Average Target
+98.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BEAM Stock